Hospital
Hendricks County Hospital
Hendricks County Hospital was paid $12.50M by Medicaid between Jan 2018 and Nov 2024, across 102 billing codes. Its largest line is 99283, emergency room visit (moderate) — 36% of everything it billed.
33Billing provider infoHENDRICKS COUNTY HOSPITAL
DANVILLE, IN 46122
DANVILLE, IN 46122
33aNPI1669475950assigned 05/31/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$12.50M
24GClaims261,390
24DCodes billed102
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Indiana
Rank by total paid#30 of 69
Median peer was paid$9.76M
This provider vs. median1.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 25,976 | $406K | |
| 2019 | 22,233 | $890K | |
| 2020 | 15,655 | $697K | |
| 2021 | 37,992 | $1.97M | |
| 2022 | 57,544 | $3.15M | |
| 2023 | 60,135 | $3.21M | |
| 2024incomplete | 41,855 | $2.18M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 36% | 29,761 | 26,261 | $4.50M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 17,134 | 14,504 | $2.21M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 8.1% | 1,608 | 782 | $1.01M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 5.5% | 11,143 | 8,589 | $686K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.6% | 6,920 | 2,096 | $577K |
| 71046 | Radiologic examination, chest; 2 views | 4.0% | 4,352 | 3,684 | $498K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 3.5% | 1,838 | 1,536 | $435K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.6% | 3,697 | 3,042 | $329K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 2.3% | 1,149 | 501 | $287K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 37,031 | 30,312 | $163K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.3% | 1,790 | 1,427 | $163K |
| 71045 | Radiologic examination, chest; single view | 1.3% | 1,107 | 923 | $162K |
90 more codes
| 80048 | Basic metabolic panel (calcium, ionized) | 1.1% | 29,315 | $140K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 335 | $123K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,671 | $118K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,053 | $110K |
| 87631 | <1% | 1,001 | $90K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 33,822 | $86K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,282 | $77K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,038 | $66K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,372 | $62K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,356 | $61K |
| 80076 | <1% | 9,018 | $46K | |
| 80053 | Comprehensive metabolic panel | <1% | 6,222 | $42K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,199 | $33K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,689 | $29K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 166 | $27K |
| 84484 | <1% | 3,495 | $26K | |
| 81025 | <1% | 4,249 | $25K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,854 | $23K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 419 | $19K |
| 81001 | <1% | 9,901 | $18K | |
| 97597 | <1% | 149 | $18K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 13 | $17K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 408 | $17K |
| 83690 | <1% | 4,475 | $16K | |
| 96367 | <1% | 338 | $16K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 279 | $14K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 119 | $13K |
| 80061 | Lipid panel | <1% | 1,227 | $12K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 20 | $11K |
| 86803 | <1% | 993 | $10K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 253 | $10K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 228 | $9K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 499 | $8K |
| 83605 | <1% | 1,118 | $8K | |
| 82728 | <1% | 831 | $7K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 265 | $6K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 119 | $6K |
| 85027 | <1% | 1,072 | $5K | |
| 83550 | <1% | 824 | $5K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 547 | $4K |
| 86762 | <1% | 415 | $4K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 283 | $4K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 41 | $4K |
| 83540 | <1% | 824 | $3K | |
| 87340 | <1% | 492 | $3K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 184 | $3K |
| 84439 | <1% | 376 | $2K | |
| 88142 | <1% | 251 | $2K | |
| 83880 | <1% | 90 | $2K | |
| 86850 | <1% | 493 | $2K | |
| 86592 | <1% | 603 | $2K | |
| 81003 | <1% | 1,306 | $2K | |
| 83655 | <1% | 120 | $1K | |
| 83970 | <1% | 58 | $1K | |
| 85379 | <1% | 195 | $1K | |
| 73630 | <1% | 28 | $1K | |
| 82607 | <1% | 122 | $1K | |
| 73564 | <1% | 22 | $959.52 | |
| 86900 | <1% | 416 | $859.48 | |
| 86901 | <1% | 416 | $856.58 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 31 | $701.80 |
| 83735 | <1% | 160 | $694.44 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 886 | $635.75 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 318 | $516.24 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 39 | $468.25 |
| 83615 | <1% | 105 | $367.39 | |
| 87660 | <1% | 30 | $365.60 | |
| 87480 | <1% | 30 | $345.55 | |
| 87510 | <1% | 30 | $345.55 | |
| 80069 | <1% | 45 | $223.67 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 14 | $198.15 |
| 82565 | <1% | 68 | $179.50 | |
| 82746 | <1% | 17 | $171.18 | |
| 84460 | <1% | 67 | $167.45 | |
| 84450 | <1% | 67 | $163.70 | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 25 | $137.20 |
| 82570 | <1% | 40 | $130.99 | |
| 83883 | <1% | 28 | $122.40 | |
| 84156 | <1% | 40 | $91.07 | |
| 85046 | <1% | 15 | $53.69 | |
| 84165 | <1% | 19 | $52.70 | |
| 84155 | <1% | 19 | $22.02 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 1,055 | $0.00 |
| 87205 | 0% | 18 | $0.00 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 182 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 165 | $0.00 |
| G0475 | Hiv antigen/antibody, combination assay, screening | 0% | 54 | $0.00 |
| 87077 | 0% | 17 | $0.00 | |
| 87070 | 0% | 18 | $0.00 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 289 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFENOUGHTY, MICHELLE (CEO)